REG - Biofrontera AG - Director/PDMR Shareholding <Origin Href="QuoteRef">B8FGn.DE</Origin>
RNS Number : 7964QBiofrontera AG03 September 2014Biofrontera AG
("Biofrontera" or the "Company")
Director Dealing
Biofrontera AG (AIM:B8F), the European biopharmaceutical company, announces that on 3 September 2014 Thomas Schaffer, the Chief Financial Officer of the Company, purchased 1,000 ordinary shares of no par value in the capital of the Company ("Ordinary Shares") at an average price of EUR 2.318. Subsequent to this transaction Mr Schaffer has a beneficial interest in 8,088 Ordinary Shares representing 0.04% of the issued ordinary share capital of the Company.
For further information, please contact:
Biofrontera AG
Prof. Hermann Lbbert, Chief Executive Officer
Thomas Schaffer , Chief Financial Officer
Tel:+ 49 (0) 214 - 87632 - 22
finnCap (Nomad and Broker)
Geoff Nash / Christopher Raggett (Corporate Finance)
Tel: 020 7220 0500
Steven Norcross(Corporate Broking)
Investor Relations
Seton Services
Toni Vallen
Tel: 020 7603 6797
Financial PR
Gable Communications
John Bick
Tel: 020 7193 7463
This information is provided by RNSThe company news service from the London Stock ExchangeENDRDSLJMMTMBBMTTI
Recent news on Biofrontera AG
See all newsRCS - Maruho Deutschland - Extraordinary General Meeting on 7 April 2022
AnnouncementREG - AIM Biofrontera AG - Cancellation - Biofrontera AG <Origin Href="QuoteRef">B8FGn.DE</Origin>
AnnouncementREG - Biofrontera AG - Private Placement <Origin Href="QuoteRef">B8FGn.DE</Origin>
AnnouncementREG - Biofrontera AG - Phase III studies update <Origin Href="QuoteRef">B8FGn.DE</Origin>
AnnouncementREG - Biofrontera AG - Excellent results in Ameluz BCC clinical study <Origin Href="QuoteRef">B8FGn.DE</Origin>
Announcement